Laura Abril
Badalona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Belantamab mafodotin for the treatment of multiple myeloma.
Journal: Expert opinion on biological therapy
Published: October 15, 2025
Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain.
Journal: Therapeutic advances in hematology
Published: April 02, 2025
Optical Genome Mapping (OGM): Validation and Clinical Utility in the Cytogenetic Diagnosis of Multiple Myeloma.
Journal: American journal of hematology
Published: March 24, 2025
First-line treatment of multiple myeloma in both transplant and non-transplant candidates.
Journal: Expert review of anticancer therapy
Published: May 17, 2023
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma.
Journal: Therapeutic advances in hematology
Published: March 14, 2021
Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era.
Journal: Annals of hematology
Published: February 05, 2021
Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma.
Journal: European journal of haematology
Published: February 05, 2021
Limited treatment options in refractory multiple myeloma: promising therapeutic developments.
Journal: Expert review of anticancer therapy
Published: December 24, 2019
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?
Journal: Clinical lymphoma, myeloma & leukemia
Published: November 15, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026